Neomorph, a San Diego-based clinical-stage biotechnology company, has raised $100M in Series B funding led by Deerfield Management. The company develops molecular glue degraders to target undruggable disease-causing proteins for oncology, Alzheimer's, and other diseases. Key asset NEO-811, an oral cereblon-dependent degrader, entered Phase 1/2 trials for clear cell renal cell carcinoma. The capital will advance clinical trials and expand the proprietary discovery platform.
TPD Funding Wave Hits 2026
Neomorph's raise follows EpiBiologics securing $107M Series B in January 2026 for its EGFR degrader. This $200M+ influx signals investor conviction in targeted protein degradation amid first PROTAC approvals expected soon. Neomorph differentiates with molecular glues over larger PROTACs used by peers like Arvinas and Kymera Therapeutics.
Undruggable Targets Limit Therapies
Over 80% of the proteome consists of undruggable proteins lacking binding pockets for traditional small molecules. Current inhibitors fail against many oncology and neurological targets, leaving diseases like ccRCC with unmet needs. Molecular glues offer event-driven pharmacology by hijacking E3 ligases for degradation.
Glues Unlock Small-Molecule Degraders
Neomorph's platform spans novel E3 ligases and degrons, enabling small, orally bioavailable glues without linkers. NEO-811 targets ccRCC via cereblon neosubstrate recruitment, with first patient dosed in February 2026. Unlike bifunctional PROTACs from Arvinas or C4 Therapeutics, glues mimic natural degradation mechanisms discovered in thalidomide analogs.
As Neomorph Co-Founder and CEO Phil Chamberlain stated:
"Neomorph, Inc.’s first-in-human study marks a major step forward for our molecular glue degrader platform, bringing our vision of differentiated, targeted therapies closer to patients who need them most."
Deerfield Leads Strategic Syndicate
Deerfield Management led the round, joined by new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital from Dana-Farber Cancer Institute. Existing backers include Novo Nordisk, Biogen, and AbbVie via partnerships worth over $3B in milestones. This mix signals growth capital for clinical scaling post-Series A ($109M in 2020).
TPD Market Scales to Billions
The targeted protein degradation market stands at $5.88B in 2026, projected to reach $12.44B by 2034 at 9.81% CAGR, per Fortune Business Insights. Big pharma deals like Neomorph's with Biogen ($1.45B potential) and Novo Nordisk ($1.46B) accelerate R&D. Molecular glues gain traction beyond PROTACs from Nurix and Monte Rosa Therapeutics.
Pioneers Drive Platform Credibility
Founders include Phil Chamberlain, ex-Celgene where he pioneered cereblon mechanisms, and Eric Fischer, who solved the DDB1-CRBN-thalidomide structure (Nature 2014). Benjamin Ebert discovered lenalidomide's degradation mode (Science 2014), while Scott Armstrong brings Dana-Farber oncology expertise. This team defined molecular glue science foundational to Neomorph's approach.
Hiring Fuels Pipeline Expansion
Post-funding, Neomorph ramped hiring for medicinal chemistry, computational roles, and IT in San Diego. Funds support NEO-811 Phase 1/2 advancement and multi-target programs from Biogen and Novo Nordisk collaborations. Recent board addition Dr. Peter Lebowitz (ex-Takeda) bolsters oncology strategy.